In addition to the 540 patients, certain subsections in the WARNINGS AND PRECAUTIONS describe adverse reactions observed with exposure to GAVRETO as a single agent in a randomized, open-label study, AcceleRET-Lung (NCT04222972), which enrolled 223 patients with RET-fusion positive locally advanced unresectable or metastatic NSCLC.
RET Fusion-Positive Non-Small Cell Lung Cancer
The safety of GAVRETO was evaluated as a single agent at 400 mg orally once daily in 281 patients with metastatic rearranged during transfection (RET fusion-positive) non-small cell lung cancer (NSCLC) in ARROW [see Clinical Studies (14.1)]. Among the 281 patients who received GAVRETO, 72% were exposed for 6 months or longer and 56% were exposed for ≥1 year.
The median age was 60 years (range: 26 to 87 years); 54% were female, 46% were White, 46% were Asian, and 4% were Hispanic/Latino.
Serious adverse reactions occurred in 65% of patients who received GAVRETO. The most frequent serious adverse reactions (in ≥ 2% of patients) were pneumonia, anemia, pneumonitis, pyrexia, sepsis, urinary tract infection, coronavirus infection, pleural effusion, dyspnea, musculoskeletal pain, pulmonary embolism, and seizure. Fatal adverse reactions occurred in 7% of patients; fatal adverse reactions which occurred in > 1 patient included pneumonia (n=8), sepsis (n=3) and COVID (n=3).
Permanent discontinuation due to an adverse reaction occurred in 20% of patients who received GAVRETO. Adverse reactions resulting in permanent discontinuation which occurred in ≥ 2% of patients included pneumonitis (3.2%), and pneumonia (2.8%).
Dosage interruptions due to an adverse reaction occurred in 73% of patients who received GAVRETO. Adverse reactions requiring dosage interruption in ≥ 2% of patients included anemia, pneumonia, pneumonitis, neutropenia, hypertension, increased blood creatine phosphokinase, fatigue, pyrexia, increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), coronavirus infection, diarrhea, hypophosphatemia, musculoskeletal pain, thrombocytopenia, dyspnea, hemorrhage, leukopenia, lymphopenia, edema, sepsis, and vomiting.
Dose reductions due to adverse reactions occurred in 51% of patients who received GAVRETO. Adverse reactions requiring dosage reductions in ≥ 2% of patients included anemia, neutropenia, pneumonitis, increased blood creatine phosphokinase, leukopenia, hypertension, fatigue, pneumonia, and lymphopenia.
Table 5 summarizes the adverse reactions in patients with NSCLC in ARROW.
Table 5: Adverse Reactions (≥ 15%) in RET Fusion-Positive NSCLC Patients Who Received GAVRETO in ARROW| Adverse reaction | GAVRETO N = 281 |
|---|
Grades 1 - 4 (%) | Grades 3 or 4 (%) |
|---|
| Gastrointestinal disorders |
| Constipation | 45 | 0.7 |
| Diarrhea | 30 | 2.5 |
| Nausea | 19 | 0 |
| Dry mouth | 17 | 0 |
| General Disorders and Administration Site Conditions |
| Edema Includes the preferred terms: Edema, Swelling face, Peripheral swelling, Generalized oedema, Edema peripheral, Face edema, Periorbital edema, Eyelid edema, Swelling, Localized edema | 44 | 0 |
| Fatigue Includes the preferred terms: Fatigue, Asthenia | 42 | 2.5 |
| Pyrexia | 29 | 0.7 |
| Musculoskeletal and Connective Tissue Disorders |
| Musculoskeletal pain Includes the preferred terms: Myalgia, Arthralgia, Pain in extremity, Neck pain, Musculoskeletal pain, Back pain, Musculoskeletal chest pain, Bone pain, Musculoskeletal stiffness | 44 | 2.5 |
| Increased Blood Creatine Phosphokinase | 19 | 9 |
| Vascular |
| Hypertension Includes the preferred terms: Hypertension, Blood pressure increased | 38 | 18 |
| Respiratory, thoracic and mediastinal disorders |
| Cough Includes the preferred terms: Cough, Productive Cough, Upper-airway cough syndrome | 36 | 0.4 |
| Dyspnea | 21 | 2.1 |
| Infection and Infestations |
| Pneumonia Includes the preferred terms: Pneumonia, Pneumocystis jirovecii pneumonia, Pneumonia cytomegaloviral, Atypical pneumonia, Lung infection, Pneumonia bacterial, Pneumonia hemophilus, Pneumonia influenzal, Pneumonia streptococcal, Pneumonia viral, Pneumonia pseudomonal | 24 | 13 |
| Urinary tract infection | 16 | 3.6 |
| Metabolism and Nutrition Disorders |
| Decreased appetite | 18 | 1.1 |
| Nervous system disorders |
| Taste disorder Includes the preferred terms: Dysgeusia, Ageusia | 17 | 0 |
| Headache Includes the preferred terms: Headache, Tension Headache | 15 | 1.1 |
| Skin and subcutaneous tissue disorders |
| Rash Includes the preferred terms: Rash, Rash maculo-papular, Dermatitis acneiform, Erythema, Rash generalized, Rash papular, Rash macular, Rash erythematous | 17 | 0 |
Clinically relevant adverse reactions occurring in < 15% of patients included pneumonitis (14%), vomiting (14%), abdominal pain (14%), and stomatitis (6%).
Table 6 summarizes the laboratory abnormalities in ARROW.
Table 6: Select Laboratory Abnormalities (≥ 20%) Worsening from Baseline in RET Fusion-Positive NSCLC Patients Who Received GAVRETO in ARROW| Laboratory Abnormality | GAVRETO
N=281
|
|---|
Grades 1-4
(%)
| Grades 3-4
(%)
|
|---|
| Chemistry |
| Increased AST | 80 | 3.2 |
| Increased ALT | 58 | 3.9 |
| Decreased albumin | 52 | 0 |
| Decreased calcium (corrected) | 50 | 1.8 |
| Decreased phosphate | 50 | 17 |
| Increased creatinine | 45 | 1.4 |
| Increased alkaline phosphatase | 43 | 2.5 |
| Decreased sodium | 42 | 10 |
| Decreased Potassium | 27 | 4.6 |
| Increased Potassium | 27 | 1.8 |
| Decreased Magnesium | 25 | 0 |
| Increased Bilirubin | 20 | 1.8 |
| Hematology |
| Decreased leukocytes | 79 | 11 |
| Decreased hemoglobin | 78 | 18 |
| Decreased lymphocytes | 73 | 32 |
| Decreased neutrophils | 70 | 21 |
| Decreased platelets | 33 | 5 |
Clinically relevant laboratory abnormalities occurring in < 20% of patients who received GAVRETO included increased magnesium (14%).
RET-altered Thyroid Cancer
The safety of GAVRETO was evaluated as a single agent at 400 mg orally once daily in 138 patients with RET-altered Thyroid Cancer (including 19 patients with RET fusion-positive thyroid cancer) in ARROW [see Clinical Studies (14.2)]. Among the 138 patients who received GAVRETO, 68% were exposed for 6 months or longer, and 40% were exposed for greater than one year.
The median age was 59 years (range: 18 to 83 years); 36% were female, 74% were White, 17% were Asian, and 6% were Hispanic/Latino.
Serious adverse reactions occurred in 39% of patients who received GAVRETO. The most frequent serious adverse reactions (in ≥ 2% of patients) were pneumonia, pneumonitis, urinary tract infection, pyrexia, fatigue, diarrhea, dizziness, anemia, hyponatremia, and ascites. Fatal adverse reaction occurred in 2.2% of patients; fatal adverse reactions that occurred in > 1 patient included pneumonia (n=2).
Permanent discontinuation due to an adverse reaction occurred in 9% of patients who received GAVRETO. Adverse reactions resulting in permanent discontinuation which occurred in > 1 patient included fatigue, pneumonia and anemia.
Dosage interruptions due to an adverse reaction occurred in 67% of patients who received GAVRETO. Adverse reactions requiring dosage interruption in ≥ 2% of patients included neutropenia, hypertension, diarrhea, fatigue, pneumonitis, anemia, increased blood creatine phosphokinase, pneumonia, urinary tract infection, musculoskeletal pain, vomiting, pyrexia, increased AST, dyspnea, hypocalcemia, cough, thrombocytopenia, abdominal pain, increased blood creatinine, dizziness, headache, decreased lymphocyte count, stomatitis, and syncope.
Dose reductions due to adverse reactions occurred in 44% of patients who received GAVRETO. Adverse reactions requiring dosage reductions in ≥ 2% of patients included neutropenia, anemia, hypertension, increased blood creatine phosphokinase, decreased lymphocyte count, pneumonitis, fatigue and thrombocytopenia.
Table 7 summarizes the adverse reactions occurring in RET-altered Thyroid Cancer Patients in ARROW.
Table 7: Adverse Reactions (≥ 15%) in RET-altered Thyroid Cancer Patients Who Received GAVRETO in ARROW| Adverse Reactions | GAVRETO
N=138
|
|---|
Grades 1-4
(%)
| Grades 3-4
(%)
|
|---|
| Musculoskeletal |
| Musculoskeletal Pain Musculoskeletal Pain includes arthralgia, arthritis, back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, musculoskeletal stiffness, myalgia, neck pain, non-cardiac chest pain, pain in extremity, spinal pain | 42 | 0.7 |
| Gastrointestinal |
| Constipation | 41 | 0.7 |
| Diarrhea Diarrhea includes colitis, diarrhea | 34 | 5 |
| Abdominal Pain Abdominal Pain includes abdominal discomfort, abdominal pain, abdominal pain upper, abdominal tenderness, epigastric discomfort | 17 | 0.7 |
| Dry mouth | 17 | 0 |
| Stomatitis Stomatitis includes mucosal inflammation, stomatitis, tongue ulceration | 17 | 0.7 |
| Nausea | 17 | 0.7 |
| Vascular |
| Hypertension | 40 | 21 |
| General |
| Fatigue Fatigue includes asthenia, fatigue | 38 | 6 |
| Edema Edema includes eyelid edema, face edema, edema, edema peripheral, periorbital edema | 29 | 0 |
| Pyrexia | 22 | 2.2 |
| Respiratory |
| Cough Cough includes cough, productive cough, upper-airway cough syndrome | 27 | 1.4 |
| Dyspnea Dyspnea includes dyspnea, dyspnea exertional | 22 | 2.2 |
| Nervous System |
| Headache Headache includes headache, migraine | 24 | 0 |
| Peripheral Neuropathy Peripheral neuropathy includes dysaesthesia, hyperaesthesia, hypoaesthesia, neuralgia, neuropathy peripheral, paraesthesia, peripheral sensory neuropathy, polyneuropathy | 20 | 0 |
| Dizziness Dizziness includes dizziness, dizziness postural, vertigo | 19 | 0.7 |
| Dysgeusia Dysgeusia includes ageusia, dysgeusia | 17 | 0 |
| Skin and Subcutaneous |
| Rash Rash includes dermatitis, dermatitis acneiform, eczema, palmar-plantar, erythrodysaesthesia syndrome, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pustular | 24 | 0 |
| Metabolism and Nutrition |
| Decreased Appetite | 15 | 0 |
Clinically relevant adverse reactions in < 15% of patients who received GAVRETO included tumor lysis syndrome and increased creatine phosphokinase.
Table 8 summarizes the laboratory abnormalities occurring in
RET-altered Thyroid Cancer Patients in ARROW.
Table 8: Select Laboratory Abnormalities (≥ 20%) Worsening from Baseline in RET-altered Thyroid Cancer Patients Who Received GAVRETO in ARROW| Laboratory Abnormality | GAVRETO
N=138
|
|---|
Grades 1-4
(%)
| Grades 3-4
(%)
|
|---|
| Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available, which ranged from 135 to 138 patients. |
| Chemistry |
| Decreased calcium (corrected) | 70 | 9 |
| Increased AST | 69 | 4.3 |
| Increased ALT | 43 | 3.6 |
| Increased creatinine | 41 | 0 |
| Decreased albumin | 41 | 1.5 |
| Decreased sodium | 28 | 2.2 |
| Decreased phosphate | 28 | 8 |
| Decreased magnesium | 27 | 0.7 |
| Increased potassium | 26 | 1.4 |
| Increased bilirubin | 24 | 1.4 |
| Increased alkaline phosphatase | 22 | 1.4 |
| Hematology |
| Decreased lymphocytes | 67 | 27 |
| Decreased hemoglobin | 63 | 13 |
| Decreased neutrophils | 59 | 16 |
| Decreased platelets | 31 | 2.9 |
Clinically relevant laboratory abnormalities in patients who received GAVRETO included increased phosphate (40%).
Other Clinical Trials Experience
AcceleRET-Lung trial (NCT04222972)
In AcceleRET-Lung trial (NCT04222972), single agent GAVRETO (n=108) was compared to chemotherapy/immunotherapy (n=104) in patients with RET fusion-positive NSCLC. Adverse reactions were infections (72% vs.52%), including pneumonia (29% vs. 6%), urinary tract infection (22% vs. 8%), and opportunistic infections (20% vs. 6%). Opportunistic infections included pneumocystis jirovecii pneumonia, fungal infections, legionella pneumonia, cytomegalovirus infection, and herpes simplex.
Strong or Moderate CYP3A and/or P-gp Inhibitors
Concomitant use with a strong or moderate CYP3A inhibitor and/or a P-gp inhibitor increases pralsetinib exposure [Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions related to GAVRETO. Avoid coadministration of GAVRETO with a strong or moderate CYP3A and/or P-gp inhibitor. If coadministration with any of the above inhibitors cannot be avoided, reduce the GAVRETO dose [see Dosage and Administration (2.4)].
Strong or Moderate CYP3A Inducers
Concomitant use with a strong CYP3A inducer decreases pralsetinib exposure [see Clinical Pharmacology (12.3)], which may decrease efficacy of GAVRETO. Avoid concomitant use of GAVRETO with strong or moderate CYP3A inducers. If coadministration of GAVRETO with strong or moderate CYP3A inducers cannot be avoided, increase the GAVRETO dose [see Dosage and Administration (2.5)]
Risk Summary
Based on findings from animal studies and its mechanism of action, GAVRETO can cause fetal harm when administered to a pregnant woman
[see
Clinical Pharmacology (12.1)].
There are no available data on GAVRETO use in pregnant women to inform drug-associated risk. Oral administration of pralsetinib to pregnant rats during the period of organogenesis resulted in malformations and embryolethality at maternal exposures below the human exposure at the clinical dose of 400 mg once daily
(see
Data).
Advise pregnant women of the potential risk to a fetus.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Data
Animal Data
In an embryo-fetal development study, once daily oral administration of pralsetinib to pregnant rats during the period of organogenesis resulted in 100% post-implantation loss at dose levels ≥ 20 mg/kg (approximately 1.8 times the human exposure based on area under the curve [AUC] at the clinical dose of 400 mg). Post-implantation loss also occurred at the 10 mg/kg dose level (approximately 0.6 times the human exposure based on AUC at the clinical dose of 400 mg). Once daily oral administration of pralsetinib at dose levels ≥ 5 mg/kg (approximately 0.2 times the human AUC at the clinical dose of 400 mg) resulted in an increase in visceral malformations and variations (absent or small kidney and ureter, absent uterine horn, malpositioned kidney or testis, retroesophageal aortic arch) and skeletal malformations and variations (vertebral and rib anomalies and reduced ossification).
Risk Summary
There are no data on the presence of pralsetinib or its metabolites in human milk or their effects on either the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with GAVRETO and for 1 week after the last dose.
Pregnancy Testing
Verify pregnancy status of females of reproductive potential prior to initiating GAVRETO
[see
Use in Specific Populations (8.1)].
Contraception
GAVRETO can cause fetal harm when administered to a pregnant woman
[see
Use in Specific Populations (8.1)].
Females
Advise females of reproductive potential to use effective non-hormonal contraception during treatment with GAVRETO and for 2 weeks after the last dose. GAVRETO may render hormonal contraceptives ineffective.
Males
Advise males with female partners of reproductive potential to use effective contraception during treatment with GAVRETO and for 1 week after the last dose.
Infertility
Based on histopathological findings in the reproductive tissues of male and female rats and a dedicated fertility study in which animals of both sexes were treated and mated to each other, GAVRETO may impair fertility
[see
Nonclinical Toxicology (13.1)].
Animal Toxicity Data
In a 4-week repeat-dose toxicology study in non-human primates, physeal dysplasia in the femur occurred at doses resulting in exposures similar to the human exposure (AUC) at the clinical dose of 400 mg. In rats there were findings of increased physeal thickness in the femur and sternum as well as tooth (incisor) abnormalities (fractures, dentin matrix alteration, ameloblast/odontoblast degeneration, necrosis) in both 4- and 13-week studies at doses resulting in exposures similar to the human exposure (AUC) at the clinical dose of 400 mg. Recovery was not assessed in the 13-week toxicology study, but increased physeal thickness in the femur and incisor degeneration did not show evidence of complete recovery in the 28-day rat study.
Monitor growth plates in adolescent patients with open growth plates. Consider interrupting or discontinuing therapy based on the severity of any growth plate abnormalities and based on an individual risk-benefit assessment.
Cardiac Electrophysiology
The QT interval prolongation potential of pralsetinib was assessed in 34 patients with RET-altered solid tumors administered GAVRETO at the recommended dosage. No large mean increase in QTc (> 20 ms) was detected in the study.
Absorption
The median time to peak concentration (Tmax) ranged from 2 to 4 hours following single doses of pralsetinib 60 mg to 600 mg.
Food Effect
Following administration of a single dose of 200 mg with a high-fat meal, (approximately 800 to 1000 calories with 50 to 60% of calories from fat), the mean Cmax of pralsetinib was increased by 2.0-fold, the mean AUC0-INF was increased by 2.2-fold, and the median Tmax was delayed from 4 to 8.5 hours, compared to the fasted state.
Distribution
The mean (CV%) apparent volume of distribution (Vd/F) of pralsetinib is 303 L (68%). Protein binding of pralsetinib is 97% and is independent of concentration. The blood-to-plasma ratio is 0.6 to 0.7.
Elimination
The mean (±standard deviation) plasma elimination half-life (T½) of pralsetinib is 16 hours (10) following single doses and 20 hours (12) following multiple doses of pralsetinib. The mean (CV%) apparent oral clearance (CL/F) of pralsetinib is 11 L/h (66%) at steady state.
Metabolism
Pralsetinib is primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6 and CYP1A2, in vitro. Following a single oral dose of 310 mg of radiolabeled pralsetinib, pralsetinib metabolites from oxidation and glucuronidation were detected as 5% or less.
Excretion
Approximately 73% (66% as unchanged) of the total administered radioactive dose [14C] pralsetinib was recovered in feces and 6% (4.8% as unchanged) was recovered in urine.
Specific Populations
No clinically significant differences in the PK of pralsetinib were observed based on age (19 to 87 years), sex, race (White, Black, or Asian), and body weight (32 to 128 kg). Mild and moderate renal impairment (CLcr 30 - 89 mL/min) had no effect on the exposure of pralsetinib. Pralsetinib has not been studied in patients with severe renal impairment (CLcr < 15 mL/min).
Drug Interaction Studies
Clinical Studies and Model-Informed Approach
CYP3A Inhibitors: Coadministration of multiple doses of CYP3A inhibitors increases pralsetinib Cmax and AUC.
Table 9: Observed or Predicted Increase in Pralsetinib Exposure after Coadministration of CYP3A Inhibitors| Type of inhibitor | Coadministered CYP3A Inhibitor | Increase in pralsetinib C
max | Increase in pralsetinib AUC |
|---|
| | Observed |
| P-gp and Strong CYP3A Inhibitor | Itraconazole (200 mg twice daily on Day 1, followed by 200 mg once daily) | 1.8-fold | 3.5-fold |
| | Predicted |
| Strong CYP3A Inhibitors | Voriconazole (400 mg twice daily on Day 1, followed by 200 mg twice daily) | 1.2-fold | 2.2-fold |
| Combined P-gp and Moderate CYP3A Inhibitors | Verapamil (80 mg three times daily) | 1.6-fold | 2.1-fold |
| Moderate CYP3A Inhibitors | Fluconazole (400 mg once daily) | 1.2-fold | 1.7-fold |
P-gp Inhibitors: Coadministration of cyclosporine (single 600 mg dose) with a single 200 mg dose of pralsetinib in healthy subjects increased pralsetinib AUC0-inf by 1.8-fold and Cmax by 1.5-fold, relative to a 200 mg dose of pralsetinib administered alone.
Strong CYP3A Inducers: Coadministration of rifampin 600 mg once daily with a single GAVRETO 400 mg dose decreased pralsetinib AUC0-INF by 68% and Cmax by 30%.
Moderate CYP3A Inducers: Coadministration of multiple doses of efavirenz (600 mg once daily) is predicted to decrease the pralsetinib AUC by 45% and Cmax by 18%.
Mild CYP3A Inducers: No clinically significant differences in the PK of pralsetinib were identified when GAVRETO was coadministered with mild CYP3A inducers.
Acid-Reducing Agents: No clinically significant differences in the PK of pralsetinib were observed when GAVRETO was coadministered with gastric acid reducing agents.
In Vitro Studies
Cytochrome P450 (CYP) Enzymes: Pralsetinib is a time-dependent inhibitor of CYP3A and an inhibitor of CYP2C8, CYP2C9, and CYP3A, but not an inhibitor of CYP1A2, CYP2B6, CYP2C19 or CYP2D6 at clinically relevant concentrations.
Pralsetinib is an inducer of CYP2C8, CYP2C9, and CYP3A, but not an inducer of CYP1A2, CYP2B6, or CYP2C19 at clinically relevant concentrations.
Transporter Systems: Pralsetinib is a substrate of P-gp and BCRP, but not a substrate of BSEP, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, MATE2-K, OAT1, or OAT3.
Pralsetinib is an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, MATE2-K, and BSEP, but not an inhibitor of OCT1, OCT2, and OAT1A3 at clinically relevant concentrations.
Metastatic
RET Fusion-Positive NSCLC Previously Treated with Platinum Chemotherapy
Efficacy was evaluated in 130 patients with
RET fusion-positive NSCLC with measurable disease who were previously treated with platinum chemotherapy enrolled into a cohort of ARROW.
The median age was 59 years (range: 26 to 85); 51% were female, 40% were White, 50% were Asian, 4.6% were Hispanic/Latino. ECOG performance status was 0-1 (95%) or 2 (3.8%), 99% of patients had metastatic disease, and 41% had either a history of or current CNS metastasis. Patients received a median of 2 prior systemic therapies (range 1–6); 42% had prior anti-PD-1/PD-L1 therapy and 27% had prior kinase inhibitors. A total of 48% of the patients received prior radiation therapy.
RET fusions were detected in 80% of patients using NGS (37% tumor samples; 15% blood or plasma samples, 28% unknown), 13% using FISH, and 2% using other methods. The most common
RET fusion partners were KIF5B (70%) and CCDC6 (19%).
Efficacy results for
RET fusion-positive NSCLC patients who received prior platinum-based chemotherapy are summarized in Table 10.
Table 10: Efficacy Results in ARROW (Metastatic RET Fusion-Positive NSCLC Previously Treated with Platinum Chemotherapy)| Efficacy Parameter | GAVRETO
N=130
|
|---|
| NE = not estimable |
| Overall Response Rate (ORR) Confirmed overall response rate assessed by BICR (95% CI) | 63 (54, 71) |
| Complete Response, % | 6 |
| Partial Response, % | 57 |
| Duration of Response (DOR) | N=82 |
| Median, months (95% CI) | 38.8 (14.8, NE) |
| Patients with DOR ≥ 12-months Based on observed duration of response , % | 66 |
For the 54 patients who received an anti-PD-1 or anti-PD-L1 therapy, either sequentially or concurrently with platinum-based chemotherapy, an exploratory subgroup analysis of ORR was 59% (95% CI: 45, 72) and the median DOR was 22.3 months (95% CI: 8.0, NE).
Among the 130 patients with
RET fusion-positive NSCLC, 10 had measurable CNS metastases at baseline as assessed by BICR. No patients received radiation therapy (RT) to the brain within 2 months prior to study entry. Responses in intracranial lesions were observed in 7 of these 10 patients including 2 patients with a CNS complete response; 71% of responders had a DOR of ≥ 6 months.
Treatment-naïve
RET Fusion-Positive NSCLC
Efficacy was evaluated in 107 patients with treatment-naïve
RET fusion-positive NSCLC with measurable disease enrolled into ARROW.
The median age was 62 years (range 30 to 87); 53% were female, 49% were White, 45% were Asian, and 2.8% were Hispanic or Latino. ECOG performance status was 0-1 for 99% of the patients and 98% of patients had metastatic disease; 28% had either history of or current CNS metastasis.
RET fusions were detected in 68% of patients using NGS (30% tumor samples; 17% blood or plasma; 22% unknown) and 19% using FISH. The most common RET fusion partners were KIF5B (71%) and CCDC6 (18%).
Efficacy results for treatment-naïve RET fusion-positive NSCLC are summarized in Table 11.
Table 11: Efficacy Results for ARROW (Treatment-Naïve Metastatic RET Fusion-Positive NSCLC)| Efficacy Parameter | GAVRETO
N=107
|
|---|
| Overall Response Rate (ORR) Confirmed overall response rate assessed by BICR (95% CI) | 78 (68, 85) |
| Complete Response, % | 7 |
| Partial Response, % | 71 |
| Duration of Response (DOR) | N=83 |
| Median, months (95% CI) | 13.4 (9.4, 23.1) |
| Patients with DOR ≥ 12-months Based on observed duration of response , % | 45 |
Serious Infections, Including Opportunistic Infections
Advise patients that GAVRETO may increase the risk of serious infections and to contact their healthcare provider if they experience symptoms of infections [see Warnings and Precautions (5.1)].
ILD/Pneumonitis
Advise patients to contact their healthcare provider if they experience new or worsening respiratory symptoms [see Warnings and Precautions (5.2)].
Hypertension
Advise patients that they will require regular blood pressure monitoring and to contact their healthcare provider if they experience symptoms of increased blood pressure or elevated readings [see Warnings and Precautions (5.3)].
Hepatotoxicity
Advise patients that hepatotoxicity can occur and to immediately contact their healthcare provider for signs or symptoms of hepatotoxicity [see Warnings and Precautions (5.4)].
Hemorrhagic Events
Advise patients that GAVRETO may increase the risk for bleeding and to contact their healthcare provider if they experience any signs or symptoms of bleeding [see Warnings and Precautions (5.5)].
Tumor Lysis Syndrome
Advise patients to contact their healthcare provider promptly to report any signs and symptoms of TLS [see Warnings and Precautions (5.6)].
Risk of Impaired Wound Healing
Advise patients that GAVRETO may impair wound healing. Advise patients that temporary interruption of GAVRETO is recommended prior to any elective surgery [see Warnings and Precautions (5.7)].
Embryo-Fetal Toxicity
Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.8), Use in Specific Populations (8.1)].
Advise females of reproductive potential to use effective non-hormonal contraception during the treatment with GAVRETO and for 2 weeks after the last dose [see Use in Specific Populations (8.3)].
Advise males with female partners of reproductive potential to use effective contraception during treatment with GAVRETO and for 1 week after the last dose [see Use in Specific Populations (8.3)].
Lactation
Advise women not to breastfeed during treatment with GAVRETO and for 1 week after the last dose
[see
Use in Specific Populations (8.2)].
Infertility
Advise males and females of reproductive potential that GAVRETO may impair fertility
[See
Use in Specific Populations (8.3)].
Drug Interactions
Advise patients and caregivers to inform their healthcare provider of all concomitant medications,
including prescription medicines, over-the-counter drugs, vitamins, and herbal products
[see
Drug Interactions (7.1)].
Administration
Advise patients to take GAVRETO on an empty stomach (no food intake for at least 2 hours before and at least 1 hour after taking GAVRETO)
[see
Dosage and Administration (2.2)].
GAVRETO® [pralsetinib]
Manufactured for:
Rigel Pharmaceuticals, Inc.
South San Francisco, CA 94080
GAVRETO® is a registered trademark of Rigel Pharmaceuticals, Inc.
For more information go to www.GAVRETO.com or call 1-800-983-1329.
12/2025